391 papers
This study demonstrates that Aurora kinase A (AURKA) drives collective breast cancer invasion and metastasis by establishing a leader cell phenotype through centrosome polarization and by stabilizing cell-cell cohesion via its interaction with the actin regulator EPLIN.
This study reveals that small cell lung cancer (SCLC) relies on a hyperactive nonsense-mediated decay (NMD) pathway to degrade immunogenic frameshift mutations and evade immune detection, identifying NMD inhibition as a novel therapeutic strategy that simultaneously induces tumor cell death and enhances immunotherapy efficacy by boosting neoantigen presentation.
Through comprehensive whole-genome and transcriptome analyses, this study identifies three distinct molecular subtypes (G1-G3) of malignant peripheral nerve sheath tumors with unique genomic identities and progression paths, offering a new framework for diagnosis and precision oncology that transcends the limitations of PRC2-based classification.
This study utilizes single-cell longitudinal sequencing of metastatic urothelial carcinoma to reveal that macrophage reprogramming toward pro-tumoral states, alongside tumor antigen presentation loss and T-cell dysfunction, drives resistance to PD-(L)1 blockade, offering a framework for personalized immunotherapy strategies.
This study identifies DHHC7 as a critical palmitoyl transferase that modifies KRAS4A at Cys180 to drive its membrane nanoclustering and downstream RAF signaling, thereby promoting pancreatic cancer growth and highlighting DHHC7 as a promising therapeutic target for KRAS-mutant cancers.
This study employs an integrative meta-analysis of transcriptomic data to identify consensus miRNA signatures that distinguish melanoma progression stages, revealing specific regulatory axes (miR-142-5p/CDK6 and miR-223-3p/RHOB) that drive senescence escape and stress-adaptive invasiveness, thereby offering novel biomarkers for diagnosis and therapeutic targets for prognosis.
Androgen receptor inhibitors enhance natural killer (NK) cell-mediated killing of prostate cancer cells but also upregulate the inhibitory ligand HLA-E, a mechanism that can be overcome to further boost therapeutic efficacy by combining AR inhibitors with NKG2A checkpoint blockade.
This study reveals that platelet-mediated PAR4 signaling drives sex-dependent glioblastoma progression by suppressing CD8+ T cell infiltration through a novel PAR4-ERβ interaction, thereby conferring a survival benefit to females that is abolished in males or upon estrogen depletion.
The authors introduce RESTRICT-seq, a novel time-gated CRISPR screening methodology that restricts Cas9 activity to controlled cycles to reduce noise and improve signal-to-noise ratios, successfully identifying PAK1 as a key epigenetic driver of treatment resistance in cutaneous squamous cell carcinoma.
This study reveals that in small cell lung cancer, ASCL1-high cell states resist ferroptosis by upregulating GCH1 to boost antioxidant levels, whereas ASCL1-low states undergo ferroptosis upon cysteine depletion, suggesting that combining cysteine depletion with BH4 synthesis inhibition effectively targets tumor heterogeneity to induce cell death.
This study identifies tumor-intrinsic IL-17 signaling as a novel mechanism driving oncolytic adenovirus resistance by promoting cancer stemness, metabolic reprogramming toward lipid metabolism, and suppression of cell death pathways, thereby establishing it as a key prognostic biomarker and therapeutic target.
This study presents the first single-cell RNA sequencing atlas of the normal adult human male breast, revealing that while it retains the same three epithelial populations as the female breast, it exhibits a distinct composition with an abundance of luminal committed cells and unique transcriptional properties characterized by elevated estrogen receptor activity, which provides a critical reference for understanding male breast cancer biology.
This study reveals that SMAD4 acts as a tumor suppressor in lung squamous cell carcinoma by non-canonically inhibiting 3D genome reorganization, specifically by sequestering EP300 to prevent aberrant enhancer-promoter looping and subsequent oncogenic SOX2 activation.
This study demonstrates that B7-H3 drives hepatocellular carcinoma progression and natural killer cell resistance by regulating cell adhesion, migration, and immune checkpoint expression through distinct oncogenic signaling pathways in epithelial and mesenchymal tumor cells.
This study demonstrates that EGFL7 promotes immune evasion in glioblastoma by interacting with integrin β2 to drive T cell exhaustion and macrophage polarization, revealing that targeting this axis enhances the efficacy of anti-PD1 immunotherapy and extends survival in mouse models.
This study integrates single-cell and bulk transcriptomic data to identify liver metastasis-related genes and develop a 15-gene prognostic scoring system (LMR score) that outperforms traditional staging and other models in predicting outcomes for colorectal cancer patients.
This study establishes a low-dose PBMC-engrafted humanized mouse model using CD47-deficient triple-knockout mice that achieves stable human leukocyte reconstitution and a significantly prolonged experimental window by mitigating lethal graft-versus-host disease, offering a versatile platform for immuno-oncology and radiotherapy research.
This study introduces a spike-in probe-enhanced single-cell RNA-seq workflow that enables robust detection and high-resolution transcriptomic profiling of synNotch-CAR-T cells in vivo, revealing their tissue-specific activation, differentiation, and therapeutic dynamics within a glioblastoma model.
This study identifies a robust, lineage-agnostic RNA splicing signature induced by PRMT5 inhibition in MTAP-deleted cancers, establishing it as a specific pharmacodynamic and predictive biomarker for monitoring the efficacy of MTA-cooperative PRMT5 inhibitors.
This study demonstrates that BRAFV600E-driven thyroid tumor development in mice triggers a heterogeneous pro-inflammatory response characterized by early cytokine expression and variable lymphocytic infiltration, which correlates with clonal differences in tumor progression and the inconsistent efficacy of BRAF inhibitor therapy.